180 related articles for article (PubMed ID: 2449025)
41. Role of biological response modifiers in immunochemotherapy of solid tumors and retroviral-induced leukemia.
Fuggetta MP; D'Onofrio C; Bonmassar E
Ann Ist Super Sanita; 1990; 26(3-4):385-95. PubMed ID: 1708953
[TBL] [Abstract][Full Text] [Related]
42. [Hematology 2010].
Dreyling M; Subklewe M; Braess J; Spiekermann K
Dtsch Med Wochenschr; 2010 Jun; 135(25-26):1322-5. PubMed ID: 20556691
[No Abstract] [Full Text] [Related]
43. [Betamethasone phosphate in hematology].
Bauters F
Lille Med; 1971 Apr; 16():S 2:625-30. PubMed ID: 5293269
[No Abstract] [Full Text] [Related]
44. [Role of interferon in the treatment of multiple myeloma].
Shimazaki C
Nihon Rinsho; 2006 Jul; 64(7):1291-6. PubMed ID: 16838647
[TBL] [Abstract][Full Text] [Related]
45. [Principles of treatment of hemoblastoses under ambulatory conditions].
Polonskaia EN; Vinogradova IuE; Lobanova NA; Iudina NI; Korovina VI
Ter Arkh; 1976; 48(8):54-60. PubMed ID: 828780
[No Abstract] [Full Text] [Related]
46. Lenalidomide, a thalidomide derivative, shows promise in various applications.
Oestreicher P
ONS Connect; 2007 Aug; 22(8):22-3. PubMed ID: 17824579
[No Abstract] [Full Text] [Related]
47. [Drug therapy in hemoblastosis].
Bischof B
Folia Clin Int (Barc); 1968 Jun; 18(6):365-8. PubMed ID: 4988909
[No Abstract] [Full Text] [Related]
48. Lenalidomide.
Weisel K; Kanz L
Recent Results Cancer Res; 2014; 201():347-57. PubMed ID: 24756803
[TBL] [Abstract][Full Text] [Related]
49. [Pleiotropic actions of interferon (author's transl)].
Suzuki J
Tanpakushitsu Kakusan Koso; 1976 Apr; 21(4):278-86. PubMed ID: 796878
[No Abstract] [Full Text] [Related]
50. Differentiation therapy.
Paquette RL; Koeffler HP
Hematol Oncol Clin North Am; 1992 Jun; 6(3):687-706. PubMed ID: 1377195
[TBL] [Abstract][Full Text] [Related]
51. [Indications of G-CSF administration in hematologic disorders].
Lionne-Huyghe P; Kuhnowski F; Coiteux V; Bauters F; Morschhauser F
Bull Cancer; 2006 May; 93(5):453-62. PubMed ID: 16777623
[TBL] [Abstract][Full Text] [Related]
52. [Antineoplastic effects of interferons].
Shimoyama M
Nihon Rinsho; 1986 Feb; 44(2):395-402. PubMed ID: 2422409
[No Abstract] [Full Text] [Related]
53. [Interferon--the prospects and problems of its use in therapeutic and oncological practice].
Poverennyĭ AM
Med Radiol (Mosk); 1983 Jun; 28(6):67-71. PubMed ID: 6191171
[No Abstract] [Full Text] [Related]
54. [Cytostatic therapy of hemoblastosis].
Ehrhart H
Pharmakotherapia; 1964; 2(1):59-88. PubMed ID: 5337120
[No Abstract] [Full Text] [Related]
55. Antitumor effects of interferon.
Gresser I; Tovey MG
Biochim Biophys Acta; 1978 Oct; 516(2):231-47. PubMed ID: 365241
[No Abstract] [Full Text] [Related]
56. Interferon in hematologic malignancies and related disorder.
Semin Hematol; 1990 Jul; 27(3 Suppl 4):1-36. PubMed ID: 1695762
[No Abstract] [Full Text] [Related]
57. [Anti-tumor effects of interferon (author's transl)].
Sun Y
Zhonghua Yi Xue Za Zhi; 1981 Sep; 61(9):556-8. PubMed ID: 6176299
[No Abstract] [Full Text] [Related]
58. Myelodysplastic syndrome with erythroid hypoplasia is a new clinical entity responsive to cyclosporin A therapy.
Shimamoto T; Ohyashiki K
Leuk Lymphoma; 2002 Sep; 43(9):1895-6. PubMed ID: 12685853
[No Abstract] [Full Text] [Related]
59. Approaches to the immunological monitoring of cancer patients treated with natural or recombinant interferons.
Herberman RB; Thurman GB
J Biol Response Mod; 1983; 2(6):548-62. PubMed ID: 6198476
[No Abstract] [Full Text] [Related]
60. [Interferons. Treatment of malignant hemopathies with interferons].
Guilhot F; Sadoun A; Delwail V
Ann Med Interne (Paris); 1993; 144(8):548-56. PubMed ID: 7513980
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
